Inspira Technologies Announces First Half 2021 Financial Results and Provides Business Update Ended the first half of 2021 with cash and cash equivalents of $4,355,000 On the path to develop potential strategic collabora

Technologies Announces First Half 2021 Financial Results and Provides Business Update

Israel / August 13, 2021/ -- Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"),

a specialty medical device company engaged in the research, development, manufacturing and marketing of proprietary respiratory support

technologies, announced today its financial results as of and

for the six months ended June 30, 2021. The Company has also released a corporate update.

"In order to achieve our

Go-To-Market objective, we are exploring potential partnerships with leading medical device companies, manufacturers, and distributors"

said Dagi Ben-Noon, Inspira's CEO and one of its Co-Founders. "We estimate that our Augmented Respiration Technology (ART)

system has a total potential addressable market of $25 billion. We plan to target the 20 million patients admitted to Intensive Care Units

(ICUs) each year who are being placed on mechanical ventilation. We have developed a "razor, razor blade" business model,

under which we expect disposable sales to grow with the future mass deployment of our ART system" Mr. Ben-Noon added.

Subsequent Corporate Highlights

Financial Results for

the Six Months Ended June 30, 2021

Technologies OXY B.H.N. Ltd.

Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough

Augmented Respiration Technology (ART), which it believes will elevate and stabilize patient oxygen saturation levels. The Company's

ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky and

costly mechanical ventilation systems that require medically induced coma. The Company's product has not yet been tested or used

in humans and has not been approved by the U.S. Food and Drug Administration (FDA).

more information, please visit our corporate website:

Statement Disclaimer

This press release contains express

or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements

when it discusses that Inspira is exploring potential partnerships with leading medical device companies, manufacturers, and distributors,

that Inspira is planning to target the 20 million patients admitted to ICUs each year who are being placed on mechanical ventilation,

that the Company's disposable sales are expected to grow with the future mass deployment of its ART system, and that the Company

plans to increase its workforce by up to 100%. These forward-looking statements and their implications are based on the current expectations

of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation

to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect

the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained

under the heading "Risk Factors" in the Company's Registration Statement on Form F-1 filed with the SEC, which is available

on the SEC's website, www.sec.gov.

INTERIM STATEMENTS OF FINANCIAL POSITION

(US dollars in thousands)

INTERIM STATEMENTS OF COMPREHENSIVE INCOME

(US dollars in thousands)

CONDENSED INTERIM STATEMENTS

OF CHANGES IN SHAREHOLDERS' EQUITY

(US dollars in thousands)

For the six month period ended June 30,